[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345778-105":59,"doc-detail-345778-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","integrating-dna-mutations-and-rna-expression-of-cancer-driver-genes-in-asian-rare-cancers-a-pan-cancer-analysis","Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers - A Pan-Cancer Analysis","","Study addresses molecular heterogeneity of rare cancers in Asia, where limited evidence complicates treatment decisions. It evaluates whether RNA expression of cancer driver genes is driven mainly by tumor lineage or by specific somatic DNA mutations, and whether genomic alteration status affects clinical outcomes. DNA and RNA from MASTER KEY Asia formalin-fixed paraffin-embedded tumors are integrated using sequencing, TPM Z-score quantification, elastic net modeling, and independent replication to assess prognostic relevance.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrating-dna-mutations-and-rna-expression-of-cancer-driver-genes-in-asian-rare-cancers-a-pan-cancer-analysis/345778/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrating-dna-mutations-and-rna-expression-of-cancer-driver-genes-in-asian-rare-cancers-a-pan-cancer-analysis/345778.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study focus on in Asian rare cancers?","Question",{"text":112,"@type":113},"It investigates whether RNA expression of cancer driver genes is primarily governed by tumor lineage or by specific somatic DNA mutations, and whether these genomic features influence treatment-related outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were genomic alterations and RNA expression analyzed?",{"text":117,"@type":113},"DNA and RNA were extracted from MASTER KEY Asia formalin-fixed paraffin-embedded tumors. Next-generation sequencing evaluated genomic alterations and gene expression, with RNA expression quantified as TPM Z scores and elastic net regression using 10-fold cross-validation; results were independently replicated in another cohort.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors predominantly determine RNA expression of cancer driver genes?",{"text":121,"@type":113},"Tumor lineage predominantly determined RNA expression for 17 of 27 driver genes (63%). In contrast, ERBB2 and MDM2 showed regulation primarily driven by genomic alterations.",{"name":123,"@type":110,"acceptedAnswer":124},"What clinical implications were observed from genomic alteration status?",{"text":125,"@type":113},"TP53 gain-of-function mutations were linked to higher disease progression rates and shorter progression-free survival than loss-of-function variants, while tumor mutational burden was not associated with treatment response. The findings support clinically meaningful information beyond transcriptional profiling alone.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},345778,1790190832,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Original Reports | Cancer Genomics  \nIntegrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis  \nKathleen Yasmin de Almeida, PhD1 ; Marcelo Severino B. Imasa, MD2; Pei Jye Voon, MD3; Hwoei Fen Soo Hoo, MD4; Tom Wei-Wu Chen, MD5; Suhana Yusak, MD6; Rangasamy Ramachandran, MSc7; Najihah Abu Bakar, MSc8  ; Ming-Huang Chen, PhD9  ; Yasushi Yatabe, PhD10  ; Kenichi Nakamura, PhD1  ; Hitomi Sumiyoshi Okuma, PhD1,11  ; and Kan Yonemori, PhD1,11   \nDOI [https://doi.org/10.1200/PO-25-00907](https://doi.org/10.1200/PO-25-00907)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Rare cancers are molecularly heterogeneous and lack robust clinical evidence to guide treatment. Whether cancer driver gene expression is governed by tumor lineage or speciﬁc somatic alterations—and whether this distinction carries clinical relevance—remains poorly characterized, particularly in Asian populations. This study aimed to determine the relative contributions of tumor lineage and DNA mutations to RNA expression of cancer driver genes and to evaluate the clinical implications of genomic alteration status in Asian patients with rare cancers. |\n| METHODS | DNA and RNA were extracted from formalin-ﬁxed parafﬁn-embedded tumor samples obtained through the MASTER KEY Asia research network. Nextgeneration sequencing was performed to evaluate genomic alterations and gene expression proﬁles. RNA expression of cancer driver genes was quantiﬁed as TPM Z scores. Elastic net regression with 10-fold cross-validation assessed the relative contributions of tumor lineage and DNA mutations to RNA expression, and ﬁndings were independently replicated in another cohort. |\n| RESULTS | Integrated DNA and RNA data were available for 128 patients. Tumor lineage was the predominant determinant of RNA expression in 17 of 27 cancer driver genes (63%), whereas ERBB2 and MDM2 demonstrated genomic-predominant regulation, replicated across both cohorts. Alterations in ERBB2 or ARID1A were associated with a lower frequency of disease progression compared with patients without either alteration (P 5 .01), independently of ERBB2 RNA expression. Functional subclassiﬁcation of TP53 revealed that gain-of-function mutations were associated with higher rates of disease progression (P 5 .007) and shorter progression-free survival than loss-of-function variants (hazard ratio, 2.355 [95% CI, 1.086 to 5.105]; P 5 . 029) . Tumor mutational burden was not associated with treatment response. |\n| CONCLUSION | These ﬁndings demonstrate that genomic alteration status, including TP53 functional subclassiﬁcation, provides clinically meaningful information beyond transcriptional proﬁling alone, supporting integrative genomics and transcriptomics analysis for precision oncology in rare cancers. |\n\nACCOMPANYING CONTENT  \n Data Sharing Statement  \n Data Supplement  \nAccepted May 22, 2026 Published June 29, 2026  \nJCO Precis Oncol 10:e2500907 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nRare cancers represent a challenging and often disregarded category in oncology.1 ,2 Although signiﬁcant strides have been made in the treatment of more prevalent cancers, the diagnosis and treatment of rare cancers continue to be a complex task. Deﬁned as malignant tumors occurring at a rate of fewer than six cases per 100,000 individuals per year, according to the deﬁnition of RARECARE in Europe, adopted in Japan,1 ,3 the rarity of these diseases often results in a lack  \nof robust clinical data, hindering the development of targeted and personalized therapies.3,4 Notably, although each of these diseases represents \u003C 1% of all cancer cases, collectively they contribute to 15% of all cancer diagnoses in Japan1 and 22% in Europe.3  \nMulti-omics approaches enable integrated analysis of multiple layers of biologic information, providing a more comprehensive view of molecular features.5–7 ","cbCailiVQsKcsXDj","https://ap.wps.com/l/cbCailiVQsKcsXDj","pdf",2339882,12,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context","[{\"question\":\"What problem does the study focus on in Asian rare cancers?\",\"answer\":\"It investigates whether RNA expression of cancer driver genes is primarily governed by tumor lineage or by specific somatic DNA mutations, and whether these genomic features influence treatment-related outcomes.\"},{\"question\":\"How were genomic alterations and RNA expression analyzed?\",\"answer\":\"DNA and RNA were extracted from MASTER KEY Asia formalin-fixed paraffin-embedded tumors. Next-generation sequencing evaluated genomic alterations and gene expression, with RNA expression quantified as TPM Z scores and elastic net regression using 10-fold cross-validation; results were independently replicated in another cohort.\"},{\"question\":\"Which factors predominantly determine RNA expression of cancer driver genes?\",\"answer\":\"Tumor lineage predominantly determined RNA expression for 17 of 27 driver genes (63%). In contrast, ERBB2 and MDM2 showed regulation primarily driven by genomic alterations.\"},{\"question\":\"What clinical implications were observed from genomic alteration status?\",\"answer\":\"TP53 gain-of-function mutations were linked to higher disease progression rates and shorter progression-free survival than loss-of-function variants, while tumor mutational burden was not associated with treatment response. The findings support clinically meaningful information beyond transcriptional profiling alone.\"}]","Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers - A Pan-Cancer Analysis | PDF",1790058853,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f32e953c982e6de22dca28c239a1f8c2.webp",983,1315,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77577a8fb70083ca8ce466dc0cb25858.webp",982,1314,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba90d67bc62f5a9f7606403d16e798bf.webp",981,1312,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f93fd973218c349d19002656f8e41127.webp",980,1311]